Home › Compare › TKFOY vs ABBV
TKFOY yields 1.83% · ABBV yields 3.06%● Live data
📍 TKFOY pulled ahead of the other in Year 4
Combined, TKFOY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of TKFOY + ABBV for your $10,000?
Tokyu Fudosan Holdings Corporation, together with its subsidiaries, engages in the real estate business in Japan and internationally. The company operates through four segments: Urban Development, Strategic Investment, Property Management & Operation, and Real Estate Agents. The Urban Development segment develops and operates office buildings, commercial facilities, condominiums, leased housing, and other facilities. The Strategic Investment segment develops and improves infrastructures, such as renewable energy power generation and logistics facilities. The Property Management & Operation segment manages condominiums, buildings and facilities, and other properties; and constructs rental conference rooms and hotels, as well as leisure, healthcare, and environmental and greening management facilities. The Real-Estate Agents segment provides real-estate sales agent service and consignment sales; and engages in operations related to rental housing management. It also owns and manages resort facilities, urban style hotels, senior housings, and membership sports clubs. The company was founded in 1918 and is headquartered in Tokyo, Japan.
Full TKFOY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.